Immunicom

Here is a peer reviewed publication that we at Immunicom authored describing how our technology is a “checkpoint inhibitor” medical device …nslational-medicine.biomedcentral.com/articles/10.11… #immunotherapy #cancer #medicine #oncology #immunology

LW-02 Cartridge: What Can the Immunicom LW-02 Therapy Do For Patients with Breast Cancer? @immunicom #LW02Therapy #autoimmune #renal #cardiovascular #immunotherapy Watch and Share the Video Here: medicusnetworks.net/3VWgwBS

Besides possessing tumor antigens, exosomes possess #cancer derived immune suppressive molecules that shut down #Immunotherapy This is why approaches such as those by @immunicom are so important...i mean approaches such as filtering them out bmccancer.biomedcentral.com/articles/10.11…

Sucking out C reactive protein from blood using #apheresis results in reduction of pathology in diverse conditions ranging from #stroke to #covid19 Extracorporeal removal really is a cool technology @immunicom is the leader of extracorporeal frontiersin.org/articles/10.33…

#ICYMI Our CEO, Amir Jafri, was interviewed on @LongevityTech on how Immunopheresis® Therapy is a platform therapy that can potentially be applied in age-related disease and longevity. Read here: tinyurl.com/2a5z4cnw #immunotherapy #autoimmune #cardiovascular #oncology

#ICYMI Our CEO, Amir Jafri, was interviewed on Oncology Tube where he summarized what Immunicom does and why it matters. Listen here: tinyurl.com/yrnmxcsf #immunotherapy #autoimmune #renal #cardiovascular #oncology

Innovative #cancertreatment device has #longevity potential @immunicom founder on how blood filtering device for treating disease outside our body can be applied in age-related disease and longevity. #aging #biotech #technology longevity.technology/news/innovativ…

#ICYMI Our CEO, Amir Jafri, shared Immunicom’s mission on #empoweredpatientpodcast and the progress we’ve made towards changing how #cancers fought. Thank you @KarenJagoda for the opportunity. Listen here: tinyurl.com/4zs3362s #immunotherapy #autoimmune #renal #cardiovascular

Imagine a new breast cancer therapy that’s effective and tolerable without the life-altering side effect of drug therapies. Learn more about the LW-02 Column for Immunopheresis® therapy delivered with the Spectra Optia® (@terumobct). bit.ly/3SGjEQB #breastcancerawareness

Introducing a new type of TNBC therapy that is not a drug or radiation – LW-02 Column, a device delivered via apheresis (Spectra Optia® @terumobct) selectively captures harmful proteins to enable the immune system to fight cancer. #BreastCancerAwareness

🚨 In Industry News! @Immunicom has been awarded $2 million by @theNCI and @NIH to initiate its first US-based clinical trial at the Baylor College of Medicine in Houston, Texas (@bcmhouston). PR 📰: bit.ly/3N17Jtc

JUSTLY is proud to welcome to the platform @immunicom, a company that creates novel immunotherapies designed to treat a variety of diseases. bit.ly/3c1ZFeL #idex #investjustly #cancer #impact @ESchattner @bjork5

We are pleased to share that NCI/NIH has awarded Immunicom a $2 Million Grant to support our first US-based clinical trial at Baylor College of Medicine. Read more: bit.ly/3xLmeNj #oncology #clinicaltrials #biotech

We are excited to share our abstract from #ASCO2022! Data show that Immunopheresis is a well-tolerated immuno-oncology option for advanced TNBC patients, both as a monotherapy and adjunct therapy. Read more: bit.ly/3x0PGxn

Data shared at #AACR22 of LW-02 Cartridge Immunopheresis® Therapy shows the CBR for patients receiving Immunopheresis treatment for more than four weeks plus chemotherapy was over 40%. Read more: bit.ly/3EXu0FS #Immunicom #Immunopheresis #oncology

We are pleased to welcome Michael Lehman, longtime CFO of Sun Microsystems, to our Board of Directors! He adds over 45 years of financial, operational, legal, managerial, & pre-IPO expertise to this new role. Read more: bit.ly/3656jOQ #oncology #immunotherapy #immunology

A successful poster session at #AACR22! Thank you to everyone who stopped by to learn more on our novel therapy, #Immunopheresis.

We are pleased to welcome Dr. Peter Farrell, founder of ResMed, to our Board of Directors! He adds over 50 years of innovative leadership in the medical industry to this new role. Read more: bit.ly/3656jOQ #oncology #immunotherapy #immunology

We are excited to share strong safety and efficacy data from our TNBC clinical trial, including complete response in a patient with mTNBC. Come find us at #AACR22 tomorrow 4/12 and meet our principal investigator, Dr. Piotr Wysocki. tinyurl.com/2nmwvtcm

We are pleased to announce Marilyn Panahi as our VP of Quality! As one of the first employees at Immunicom, she has been foundational to our mission, helping us provide the highest-quality products. Read more: bit.ly/347yATW #oncology #immunotherapy #immunology

We are pleased to announce Dr. Julie Tubbs as our VP of Molecule Production! Previously a senior scientist at Immunicom, Dr. Tubbs and her team have made notable advancements in our molecule production efforts for #Immunopheresis therapy. Read more: bit.ly/347yATW